Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc..
INTRODUCTION: Few clinical trials and cohort studies have evaluated the efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH) with preexisting M184V/I or other nucleos(t)ide reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs). Real-world data are also scarce.
METHODS: Retrospective review of treatment-experienced patients who started B/F/TAF in a cohort of PWH. HIV-RNA less than 50 copies/ml was analyzed at 48 weeks in an intention-to-treat (ITT) analysis (missing=failure) and per protocol analysis (patients with missing data or changes for reasons other than virological failure were excluded). Results were compared in patients with and without previous NRTI-RAMs.
RESULTS: Five hundred and six PWH were included (16.2% women). Median age and time with HIV infection were 52.3 and 18.9 years, respectively. At baseline, viral load was less than 50 copies/ml in 440 patients (86.6%). Overall, 69 (13.6%) participants had documented preexisting NRTI-RAMs: 57 (11.2%) M184V/I and 30 (5.9%) tenofovir RAMs. In the ITT analysis, 83% (420/506) had HIV-RNA less than 50 copies/ml [82.2% (359/437) and 88.4% (61/69) in persons without and with NRTI-RAMs, respectively ( P = 0.2)]. In the per protocol analysis 94.2% (420/445) had HIV-RNA less than 50 copies/ml [94.4% (359/380) vs. 93.8% (61/65); P = 0.2]. A total of 61 participants were excluded from the per protocol analysis (23 missing data, 19 discontinued B/F/TAF because of toxicity, 13 for other reasons, and 6 died).
CONCLUSION: Switching to B/F/TAF is well tolerated and effective in the real-world setting, even in patients with preexisting NRTI RAMs, such as M184V and RAMs conferring resistance to tenofovir. These results confirm the robustness of this combination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
AIDS (London, England) - 36(2022), 14 vom: 15. Nov., Seite 1941-1947 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Micán, Rafael [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.10.2022 Date Revised 21.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/QAD.0000000000003311 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343687151 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343687151 | ||
| 003 | DE-627 | ||
| 005 | 20231226021028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QAD.0000000000003311 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343687151 | ||
| 035 | |a (NLM)35848506 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Micán, Rafael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.2022 | ||
| 500 | |a Date Revised 21.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a INTRODUCTION: Few clinical trials and cohort studies have evaluated the efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH) with preexisting M184V/I or other nucleos(t)ide reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs). Real-world data are also scarce | ||
| 520 | |a METHODS: Retrospective review of treatment-experienced patients who started B/F/TAF in a cohort of PWH. HIV-RNA less than 50 copies/ml was analyzed at 48 weeks in an intention-to-treat (ITT) analysis (missing=failure) and per protocol analysis (patients with missing data or changes for reasons other than virological failure were excluded). Results were compared in patients with and without previous NRTI-RAMs | ||
| 520 | |a RESULTS: Five hundred and six PWH were included (16.2% women). Median age and time with HIV infection were 52.3 and 18.9 years, respectively. At baseline, viral load was less than 50 copies/ml in 440 patients (86.6%). Overall, 69 (13.6%) participants had documented preexisting NRTI-RAMs: 57 (11.2%) M184V/I and 30 (5.9%) tenofovir RAMs. In the ITT analysis, 83% (420/506) had HIV-RNA less than 50 copies/ml [82.2% (359/437) and 88.4% (61/69) in persons without and with NRTI-RAMs, respectively ( P = 0.2)]. In the per protocol analysis 94.2% (420/445) had HIV-RNA less than 50 copies/ml [94.4% (359/380) vs. 93.8% (61/65); P = 0.2]. A total of 61 participants were excluded from the per protocol analysis (23 missing data, 19 discontinued B/F/TAF because of toxicity, 13 for other reasons, and 6 died) | ||
| 520 | |a CONCLUSION: Switching to B/F/TAF is well tolerated and effective in the real-world setting, even in patients with preexisting NRTI RAMs, such as M184V and RAMs conferring resistance to tenofovir. These results confirm the robustness of this combination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a tenofovir alafenamide |2 NLM | |
| 650 | 7 | |a EL9943AG5J |2 NLM | |
| 650 | 7 | |a Reverse Transcriptase Inhibitors |2 NLM | |
| 650 | 7 | |a bictegravir |2 NLM | |
| 650 | 7 | |a 8GB79LOJ07 |2 NLM | |
| 650 | 7 | |a Emtricitabine |2 NLM | |
| 650 | 7 | |a G70B4ETF4S |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Adenine |2 NLM | |
| 650 | 7 | |a JAC85A2161 |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 4 or More Rings |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 700 | 1 | |a de Gea Grela, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Cadiñanos, Julen |e verfasserin |4 aut | |
| 700 | 1 | |a de Miguel, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Busca, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardino, Jose I |e verfasserin |4 aut | |
| 700 | 1 | |a Valencia, Eulalia |e verfasserin |4 aut | |
| 700 | 1 | |a Montes, Maria Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Montejano, Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Valero, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano, Lucía |e verfasserin |4 aut | |
| 700 | 1 | |a González-García, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Arribas, Jose R |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Carbonero, Luz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AIDS (London, England) |d 1988 |g 36(2022), 14 vom: 15. Nov., Seite 1941-1947 |w (DE-627)NLM012619280 |x 1473-5571 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:14 |g day:15 |g month:11 |g pages:1941-1947 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAD.0000000000003311 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 14 |b 15 |c 11 |h 1941-1947 | ||